News | February 11, 2021
Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
In his new role, he will lead the company's growth strategy across Africa, strengthen healthcare partnerships, and expand access to innovative diagnostic solutions
Awalgaonkar's cross-industry expertise positions him to further strengthen the company's procurement capabilities and support its long-term growth strategy
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
The appointments come as Andrew Paterson, who has spent 31 years with the company, prepares to retire
The approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial
Over the course of his career, he has also held leadership roles at Pfizer, Alembic Pharmaceuticals, and Cipla
Objective Structured Clinical Examination (OSCE) are widely used to evaluate medical students' practical competencies, communication, professionalism, and clinical decision-making
Backed by Phase 3 trial showing 24% lower risk of progression
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Subscribe To Our Newsletter & Stay Updated
